JP2022543658A5 - - Google Patents

Info

Publication number
JP2022543658A5
JP2022543658A5 JP2022507630A JP2022507630A JP2022543658A5 JP 2022543658 A5 JP2022543658 A5 JP 2022543658A5 JP 2022507630 A JP2022507630 A JP 2022507630A JP 2022507630 A JP2022507630 A JP 2022507630A JP 2022543658 A5 JP2022543658 A5 JP 2022543658A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
sequence shown
acid sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022507630A
Other languages
English (en)
Japanese (ja)
Other versions
JP7802651B2 (ja
JP2022543658A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045511 external-priority patent/WO2021026508A1/en
Publication of JP2022543658A publication Critical patent/JP2022543658A/ja
Publication of JP2022543658A5 publication Critical patent/JP2022543658A5/ja
Priority to JP2025139120A priority Critical patent/JP2025176044A/ja
Application granted granted Critical
Publication of JP7802651B2 publication Critical patent/JP7802651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022507630A 2019-08-07 2020-08-07 抗nampt抗体及びその用途 Active JP7802651B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025139120A JP2025176044A (ja) 2019-08-07 2025-08-22 抗nampt抗体及びその用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962883952P 2019-08-07 2019-08-07
US62/883,952 2019-08-07
PCT/US2020/045511 WO2021026508A1 (en) 2019-08-07 2020-08-07 Anti-nampt antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025139120A Division JP2025176044A (ja) 2019-08-07 2025-08-22 抗nampt抗体及びその用途

Publications (3)

Publication Number Publication Date
JP2022543658A JP2022543658A (ja) 2022-10-13
JP2022543658A5 true JP2022543658A5 (https=) 2023-08-16
JP7802651B2 JP7802651B2 (ja) 2026-01-20

Family

ID=74503750

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022507630A Active JP7802651B2 (ja) 2019-08-07 2020-08-07 抗nampt抗体及びその用途
JP2025139120A Pending JP2025176044A (ja) 2019-08-07 2025-08-22 抗nampt抗体及びその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025139120A Pending JP2025176044A (ja) 2019-08-07 2025-08-22 抗nampt抗体及びその用途

Country Status (7)

Country Link
US (3) US11142586B2 (https=)
EP (1) EP4010368A4 (https=)
JP (2) JP7802651B2 (https=)
CN (1) CN114929738B (https=)
AU (1) AU2020325315A1 (https=)
CA (1) CA3147020A1 (https=)
WO (1) WO2021026508A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN113614535B (zh) 2018-10-31 2024-08-16 亚利桑那大学评议会 用于辐射诱导的肺损伤的生物标志物和使用方法
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
WO2021195265A1 (en) * 2020-03-24 2021-09-30 Ampio Pharmaceuticals, Inc. Methods for treating diseases associated with respiratory viruses
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN117815243B (zh) * 2023-12-29 2025-01-24 四川大学华西医院 一种化合物在制备治疗肝纤维化的药物以及nampt抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480059C (en) 2002-03-22 2015-11-24 Amrad Operations Pty. Ltd. Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
WO2004050708A2 (en) 2002-11-29 2004-06-17 Rsr Limited Antibody for the thyrotropin receptor and uses thereof
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US9409983B2 (en) * 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
CN104684906B (zh) * 2012-05-11 2017-06-09 艾伯维公司 Nampt抑制剂
AU2015357543B2 (en) * 2014-12-05 2021-10-21 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof
PL3560953T3 (pl) * 2014-12-24 2024-05-13 Autolus Limited Komórka
CN115925932A (zh) * 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体(il-36r)的抗体
CN105055412B (zh) * 2015-08-20 2018-06-19 四川大学 Nampt抑制剂在制备治疗可卡因成瘾的药物中的用途
US20190023809A1 (en) * 2015-09-03 2019-01-24 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
CN110945128B (zh) * 2017-04-14 2023-11-03 代表亚利桑那大学的亚利桑那董事会 用于治疗肺纤维化的组合物和方法
JP7490565B2 (ja) * 2017-12-29 2024-05-27 アレクトル エルエルシー 抗tmem106b抗体及びその使用方法

Similar Documents

Publication Publication Date Title
JP2022543658A5 (https=)
JP2022031635A5 (https=)
JP2024150751A5 (https=)
KR102757960B1 (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
JP2023123726A5 (https=)
JP2019527194A5 (https=)
US20050288491A1 (en) Super-humanized antibodies against respiratory syncytial virus
JP2018535650A5 (https=)
JP2018505177A5 (https=)
JP2021514973A5 (https=)
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2014500009A5 (https=)
JP2020514277A5 (https=)
JP2019522961A5 (https=)
JP2019505527A5 (https=)
JP2023515223A5 (https=)
JP2003528052A5 (https=)
JP2017507652A5 (https=)
JP2014527814A5 (https=)
JP2013502913A5 (https=)
RU2018129874A (ru) Антитела против фактора свертывания xi
JP2024042072A5 (https=)
JP2024016024A5 (https=)
JP2024541680A5 (https=)
JP2020534370A5 (https=)